Headlands Research Acquires AMCR Institute, Adding Medical Device Expertise to the Clinical Research Site Network

AMCR Institute specializes in research for endocrine, metabolic, and other chronic conditions, in addition to medical devices

SAN FRANCISCO–(BUSINESS WIRE)–#clinicalresearch—Headlands Research, a leading multinational network of clinical trial sites, today announced the acquisition of AMCR Institute, which has been in operation for more than 20 years. The site’s team brings experience in metabolic, endocrine, and medical device research to the rapidly growing clinical research site network.

“The AMCR Institute team brings deep knowledge and years of experience to Headland Research’s priority therapeutic areas,” said Kyle Burtnett, CEO of Headlands Research. “Metabolic and endocrine disorders are highly prevalent, so effective treatments have the potential to make a large impact. The addition of AMCR Institute supports Headland Research’s goal of bringing innovative treatments to those who need them most.”

Led by principal investigator (PI) Dr. Timothy S. Bailey, FACE, FACP, CPR, the San Diego–based clinical research site specializes in metabolic, endocrine, and other chronic conditions such as type 1 and type 2 diabetes and obesity. Dr. Bailey is a board-certified endocrinologist and is certified by the Association of Clinical Research Professionals (ACRP). He and his staff have worked with thousands of volunteers in phase I-IV trials and have extensive experience with the evaluation of medical devices such as continuous glucose monitors (CGMs).

“Headlands Research and AMCR Institute have a mutual dedication to accelerate access to life-changing treatments through excellence in clinical research,” said Dr. Bailey. “As a participant-centric facility, AMCR Institute appreciates the human factor of clinical research, a quality that Headlands Research also models. We are excited about the benefits the site network brings to the future capabilities of our facility and to our participant community.”

The acquisition of AMCR Institute, now known as Headlands Research AMCR Institute, is the most recent as the company expands its clinical research site network to support more clinical trials and provide access to investigational therapies to a diverse, representative population. Headlands Research recently launched one new clinical research site and acquired two additional established sites: Headlands Research Detroit serves multiple therapeutic areas, including Alzheimer’s disease and vaccines; Headlands Research Eastern Massachusetts specializes in neurodegenerative diseases such as Alzheimer’s disease, and Clinvest Research specializes in chronic diseases including migraine and arthritis.

To learn more about Headlands Research and its extensive network of research sites, visit https://headlandsresearch.com, contact [email protected], or follow the company on LinkedIn.

About Headlands Research

Headlands Research is a multinational integrated clinical trial site organization with a mission to improve lives by advancing innovative medical therapies. Its group of exceptional sites focuses on large-volume recruitment of diverse and specialty patient populations while delivering the highest quality data. Headlands Research’s principal investigators are proven industry leaders in their fields with expertise in a wide variety of indications. Utilizing expert recruitment strategies and access to diverse patients through its site databases and physician partnerships, Headlands Research has successfully completed more than 5,000 clinical trials. Additional information about the company is available at www.headlandsresearch.com.

Contacts

Brittany Kearns

Phone: 919-270-8054

Email: [email protected]